NASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Price, News & Analysis $27.96 +0.41 (+1.49%) Closing price 04:00 PM EasternExtended Trading$27.90 -0.06 (-0.20%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Celldex Therapeutics Stock (NASDAQ:CLDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Celldex Therapeutics alerts:Sign Up Key Stats Today's Range$27.16▼$28.5450-Day Range$27.53▼$39.1852-Week Range$22.33▼$45.14Volume750,528 shsAverage Volume1.07 million shsMarket Capitalization$2.20 billionP/E RatioN/ADividend YieldN/APrice Target$64.08Consensus RatingModerate Buy Company Overview Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways. The company is headquartered in Hampton, New Jersey, and is led by co-founder Anthony Marucci, its president and chief executive officer.AI Generated. May Contain Errors. Read More Celldex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCLDX MarketRank™: 1.93005181347 of 5 starsCelldex Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 1429th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCelldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCelldex Therapeutics has a consensus price target of $64.08, representing about 129.8% upside from its current price of $27.89.Amount of Analyst CoverageCelldex Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Celldex Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($4.12) to ($4.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -6.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -6.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.34% of the float of Celldex Therapeutics has been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 10.35, which indicates bearish sentiment.Change versus previous monthShort interest in Celldex Therapeutics has recently increased by 3.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News SentimentN/A News SentimentCelldex Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.MarketBeat FollowsOnly 2 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.20% of the stock of Celldex Therapeutics is held by insiders.Percentage Held by InstitutionsCelldex Therapeutics has minimal institutional ownership at this time.Read more about Celldex Therapeutics' insider trading history. Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLDX Stock News HeadlinesCelldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis1 hour ago | globenewswire.comHC Wainwright Has Strong Estimate for CLDX FY2026 EarningsNovember 12, 2026 | americanbankingnews.comCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.November 19 at 1:00 AM | Decentralized Masters (Ad)Celldex Therapeutics (NASDAQ:CLDX) Stock Price Expected to Rise, Morgan Stanley Analyst SaysNovember 11, 2026 | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Stock Gets Price Target Bump from Canaccord Genuity GroupNovember 11, 2026 | americanbankingnews.comHead to Head Survey: Oncobiologics (NASDAQ:OTLK) and Celldex Therapeutics (NASDAQ:CLDX)November 9, 2026 | americanbankingnews.comCelldex Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 6, 2026 | markets.businessinsider.comCelldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMSee More Headlines CLDX Stock Analysis - Frequently Asked Questions How have CLDX shares performed this year? Celldex Therapeutics' stock was trading at $27.16 on January 1st, 2026. Since then, CLDX stock has increased by 2.7% and is now trading at $27.89. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.06. The biopharmaceutical company earned $400 thousand during the quarter, compared to the consensus estimate of $723 thousand. When did Celldex Therapeutics' stock split? Shares of Celldex Therapeutics reverse split before market open on Monday, February 11th 2019.The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Celldex Therapeutics' major shareholders? Celldex Therapeutics' top institutional investors include State Street Corp (4.43%), Baker BROS. Advisors LP (3.27%), Goldman Sachs Group Inc. (2.06%) and Fisher Asset Management LLC (1.59%). Insiders that own company stock include Anthony S Marucci, Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi and Diane C Young. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Micron Technology (MU), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD) and Tesla (TSLA). Company Calendar Last Earnings11/05/2026Today11/19/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CLDX's financial health is in the Yellow zone, according to TradeSmith. CLDX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CLDX CIK744218 Webwww.celldex.com Phone(908) 200-7500Fax908-454-1911Employees198Year Founded1983Price Target and Rating Average Price Target for Celldex Therapeutics$64.08 High Price Target$100.00 Low Price Target$34.00 Potential Upside/Downside+129.2%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($4.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$258.76 million Net MarginsN/A Pretax Margin-195,608.84% Return on Equity-52.66% Return on Assets-47.58% Debt Debt-to-Equity RatioN/A Current Ratio10.97 Quick Ratio10.97 Sales & Book Value Annual Sales$158 thousand Price / Sales13,902.49 Cash FlowN/A Price / Cash FlowN/A Book Value$8.27 per share Price / Book3.38Miscellaneous Outstanding Shares78,562,000Free Float74,477,000Market Cap$2.20 billion OptionableOptionable Beta1.04 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CLDX) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWhile the Dow fell 89%, one stock paid a $56 dividendHomestake Mining shares rose from roughly $80 to $544 by 1936, a 580% gain, while the Dow was down 89% during ...Golden Portfolio | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.